Literature DB >> 31858130

Does an optimal management of brain metastases from oncogenic-driver non-small cell lung cancer exist?

Roberta Rudà1, Riccardo Soffietti1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31858130      PMCID： PMC7032630          DOI： 10.1093/neuonc/noz238

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  10 in total

1.  Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.

Authors:  Suresh K Balasubramanian; Mayur Sharma; Vyshak A Venur; Philipp Schmitt; Rupesh Kotecha; Samuel T Chao; John H Suh; Lilyana Angelov; Alireza M Mohammadi; Michael A Vogelbaum; Gene H Barnett; Xuefei Jia; Nathan A Pennell; Manmeet S Ahluwalia
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

2.  CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Thanyanan Reungwetwattana; Kazuhiko Nakagawa; Byoung Chul Cho; Manuel Cobo; Eun Kyung Cho; Alessandro Bertolini; Sabine Bohnet; Caicun Zhou; Ki Hyeong Lee; Naoyuki Nogami; Isamu Okamoto; Natasha Leighl; Rachel Hodge; Astrid McKeown; Andrew P Brown; Yuri Rukazenkov; Suresh S Ramalingam; Johan Vansteenkiste
Journal:  J Clin Oncol       Date:  2018-08-28       Impact factor: 44.544

3.  The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases.

Authors:  Paul W Sperduto; T Jonathan Yang; Kathryn Beal; Hubert Pan; Paul D Brown; Ananta Bangdiwala; Ryan Shanley; Norman Yeh; Laurie E Gaspar; Steve Braunstein; Penny Sneed; John Boyle; John P Kirkpatrick; Kimberley S Mak; Helen A Shih; Alex Engelman; David Roberge; Nils D Arvold; Brian Alexander; Mark M Awad; Joseph Contessa; Veronica Chiang; John Hardie; Daniel Ma; Emil Lou; William Sperduto; Minesh P Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-06-14       Impact factor: 7.038

Review 4.  Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC).

Authors:  Nicolaus Andratschke; Johannes Kraft; Carsten Nieder; Rebecca Tay; Raffaele Califano; Riccardo Soffietti; Matthias Guckenberger
Journal:  Lung Cancer       Date:  2018-12-10       Impact factor: 5.705

5.  Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.

Authors:  William J Magnuson; Nataniel H Lester-Coll; Abraham J Wu; T Jonathan Yang; Natalie A Lockney; Naamit K Gerber; Kathryn Beal; Arya Amini; Tejas Patil; Brian D Kavanagh; D Ross Camidge; Steven E Braunstein; Lauren C Boreta; Suresh K Balasubramanian; Manmeet S Ahluwalia; Niteshkumar G Rana; Albert Attia; Scott N Gettinger; Joseph N Contessa; James B Yu; Veronica L Chiang
Journal:  J Clin Oncol       Date:  2017-01-23       Impact factor: 44.544

Review 6.  Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions.

Authors:  J Remon; N Vilariño; N Reguart
Journal:  Cancer Treat Rev       Date:  2018-02-08       Impact factor: 12.111

Review 7.  Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine.

Authors:  Minjee Kim; Sani H Kizilbash; Janice K Laramy; Gautham Gampa; Karen E Parrish; Jann N Sarkaria; William F Elmquist
Journal:  Pharm Res       Date:  2018-07-12       Impact factor: 4.200

8.  Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.

Authors:  Antonin Levy; Corinne Faivre-Finn; Baktiar Hasan; Eleonora De Maio; Anna S Berghoff; Nicolas Girard; Laurent Greillier; Sylvie Lantuéjoul; Mary O'Brien; Martin Reck; Anne-Marie C Dingemans; Silvia Novello; Thierry Berghmans; Benjamin Besse; Lizza Hendriks
Journal:  Eur J Cancer       Date:  2018-02-21       Impact factor: 9.162

9.  CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).

Authors:  Yi-Long Wu; Myung-Ju Ahn; Marina Chiara Garassino; Ji-Youn Han; Nobuyuki Katakami; Hye Ryun Kim; Rachel Hodge; Paramjit Kaur; Andrew P Brown; Dana Ghiorghiu; Vassiliki A Papadimitrakopoulou; Tony S K Mok
Journal:  J Clin Oncol       Date:  2018-07-30       Impact factor: 44.544

10.  Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

Authors:  Alice T Shaw; Enriqueta Felip; Todd M Bauer; Benjamin Besse; Alejandro Navarro; Sophie Postel-Vinay; Justin F Gainor; Melissa Johnson; Jorg Dietrich; Leonard P James; Jill S Clancy; Joseph Chen; Jean-François Martini; Antonello Abbattista; Benjamin J Solomon
Journal:  Lancet Oncol       Date:  2017-10-23       Impact factor: 41.316
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.